Stockreport

SELLAS Life Sciences Group and World-Renowned Cancer Center to Study Galinpepimut-S (GPS) in Combination with Nivolumab in Patients with Malignant Pleural Mesothelioma (MPM)

SELLAS Life Sciences Group, Inc.  (SLS) 
Last sellas life sciences group, inc. earnings: 11/14 04:41 pm Check Earnings Report
PDF Initiation of Phase 1 Clinical Trial in Relapsed or Refractory MPM Expected in the Second Quarter of 2019 Previous Combination Study of GPS and Nivolumab Given After Sa [Read more]